Status:
COMPLETED
The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition
Lead Sponsor:
Saint John's Cancer Institute
Collaborating Sponsors:
Institute for Systems Biology
St. Joseph's Healthcare Foundation
Conditions:
Alzheimer Disease
Mild Cognitive Impairment
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
The PREVENTION Trial is a 12-month, two-arm randomized clinical trial (RCT) in adults 50-80 years old experiencing cognitive decline. Our study clinicians will refer patients for enrollment based on t...
Detailed Description
Subject identification and recruitment - All participants will be recruited from the Pacific Brain Health Center in Santa Monica, which is a high-volume memory-care and dementia outpatient clinic with...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Subjects must be age 50 to 80 at time of informed consent.
- Subjects of any gender, race or ethnicity are eligible to enroll in the study.
- Subjects must have a FAST stage of 2-4.
- Subjects with FAST Stage 4 must have a caregiver or legally appointed representative willing to accompany participants to the required procedures.
- As part of the study screening procedure, subjects must be willing to undergo an amyloid PET scan or have previously undergone an amyloid PET scan and agree to make the results available. Subjects must be amyloid positive to be eligible to enroll in the study.
- Subjects must be proficient in spoken and written English for consenting as well as for study participation since the intervention in this study (e.g., coaching program) is currently only available in English.
- Subjects with medical conditions must be stable for these conditions. Stable control on medication is acceptable. Subjects should not have started any new medications for chronic conditions within the last three months.
- A neurological and physical evaluation will be conducted prior to enrollment of the study by a qualified medical doctor and confirmed through medical records that they do not possess any abnormal physical or neurological sign, and/ whether they are considered to be clinically significant. Also an MMSE \>19 will be confirmed by a medical doctor prior to study enrollment.
- Subjects, with or without assistance, must be able to use a computer and web interface. If assistance is needed, it must be readily available to them.
- Subjects must be able to converse with a coach telephonically. Video-based telephone coaching is part of data-driven health coaching.
- Subjects must have regular access to a computer and the Internet along with dedicated email address since certain aspects of the program (e.g. cognitive training) are delivered electronically.
- Subject must have normal visual acuity (or corrected to normal) and normal color vision as indicated by self-report.
- Subject must have adequate hearing acuity as indicated by self-report.
- Subject must have adequate motor capacity to use a mobile phone/iPad/computer as indicated by self-report and confirmed by staff before they are enrolled into a treatment arm.
- Subject must be cleared by a physician to participate in a moderately intensive exercise program.
- Exclusion Criteria
- Subjects with an existing diagnosis of a non-AD neurodegenerative disorder (e.g., Lewy Body Dementia, Frontal-Temporal Dementia).
- Subjects with a diagnosis of cerebrovascular disease as the primary cause of cognitive impairment.
- A previously reported AD high-risk mutation (e.g., in the Presenilin Protein (PSEN) or Amyloid Precursor Protein (APP) genes) in the participant or immediate family (children, siblings, or parents). Such patients may accumulate amyloid faster than in late onset AD, and therefore may show less pronounced benefit from intervention.
- Mini Mental State Exam (MMSE) below 20.
- Clinical Dementia Rating (CDR) global score of 2 or above.
Exclusion
Key Trial Info
Start Date :
July 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2025
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT04082611
Start Date
July 12 2019
End Date
April 10 2025
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pacific Brain Health Center
Santa Monica, California, United States, 90404